Welcome to our dedicated page for Neuronetics SEC filings (Ticker: STIM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Neuronetics, Inc. (NASDAQ: STIM) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Neuronetics is a commercial stage medical technology and healthcare company focused on NeuroStar Advanced Therapy, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment, and on operating Greenbrook TMS treatment centers across the United States. Its filings offer detailed insight into how this device-and-clinic model is reflected in reported revenues, capital structure, and risk disclosures.
Among the most relevant documents for STIM are current reports on Form 8-K, which Neuronetics uses to announce quarterly financial and operating results, amendments to its credit agreement with Perceptive Credit Holdings IV, LP, and other material events. These filings confirm that the company’s common stock is listed on The Nasdaq Global Market and provide information on revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue from Greenbrook centers. Form 8-Ks also describe leadership changes, such as the appointment of a new Chief Financial Officer and a planned CEO retirement, and summarize key terms of executive employment and compensation arrangements.
Investors reviewing Neuronetics’ filings can also examine disclosures about its credit facility, including additional borrowing tranches, minimum liquidity requirements, and associated warrant issuances. Safe harbor statements in these reports outline forward-looking risks related to reliance on NeuroStar Advanced Therapy System sales and usage, payer coverage and reimbursement for TMS treatments, competition from other technologies, and the integration of Greenbrook’s clinic business.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that highlight the main points of lengthy documents such as 10-K annual reports, 10-Q quarterly reports, and 8-K current reports. Users can quickly see how Neuronetics presents its business model, revenue drivers, and risk factors, and can also track insider and equity-related activity through filings that describe inducement equity awards and warrant issuances. Real-time updates from EDGAR ensure that new Neuronetics filings, including financial results and material agreements, are available promptly with simplified explanations for faster analysis.
Neuronetics (STIM) reported Q3 2025 results. Revenue rose to $37.3 million from $18.5 million, reflecting the Greenbrook acquisition and a new services mix. U.S. clinic revenue contributed $21.8 million (60% of U.S. revenue), while treatment sessions were $10.5 million and NeuroStar systems were $3.5 million.
Gross profit was $17.1 million versus $14.0 million a year ago. The company posted a loss from operations of $7.3 million and a net loss of $9.4 million, improving from a $13.3 million net loss last year. EPS was ($0.13) versus ($0.44).
Liquidity strengthened through a February secondary offering of 9.2 million shares at $2.25 (net proceeds $18.9 million) and an at-the-market program that sold 2,261,835 shares for gross $8.3 million (net $7.8 million), leaving about $41.7 million available. Cash and cash equivalents were $28.0 million with $6.5 million restricted, and long-term debt, net, was $65.7 million; $70.0 million is outstanding under the Perceptive facility maturing in July 2029. Shares outstanding were 68.5 million as of October 29, 2025.
Neuronetics, Inc. (STIM) filed an 8-K announcing it furnished a press release with financial results for the three months ended September 30, 2025 (Exhibit 99.1) and an investor presentation (Exhibit 99.2). The materials are furnished, not filed, under the Exchange Act.
The company also disclosed a planned leadership transition: President & CEO Keith J. Sullivan intends to retire on June 30, 2026. A search for his successor has begun. He will continue in his role until a successor is appointed and then serve as a consultant to support a seamless transition. The company stated his decision was not due to any dispute or disagreement.
Neuronetics (STIM) reported an insider equity award on Form 4. A director acquired 10,531 shares of common stock on 10/20/2025 through a restricted stock unit award that vested immediately, elected in lieu of a cash retainer. The transaction was recorded at $0 per unit, consistent with RSU grants.
Following this transaction, the director’s beneficial ownership stands at 588,767 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider equity award. On 10/20/2025, a director acquired 7,326 shares of common stock at $0, coded “A,” under the company’s non-employee director compensation plan. The award reflects an election to receive stock in lieu of a cash retainer, delivered as restricted stock units that vested immediately upon grant, with each RSU equal to one share.
Following the transaction, the director beneficially owned 221,716 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider equity award by a director. On 10/20/2025, the director acquired 7,554 shares of common stock via a restricted stock unit (RSU) grant at $0 under the non-employee directors compensation plan, electing stock in lieu of a cash retainer.
The RSU award vested immediately upon grant, with each RSU representing one share. Following the transaction, the director’s beneficial ownership stands at 371,816 shares, held directly.
Neuronetics, Inc. (STIM) reported an insider transaction by a director. On 10/20/2025, the director acquired 6,410 shares of common stock via a restricted stock unit (RSU) grant that vested immediately and was elected in lieu of a cash retainer under the non-employee directors compensation plan. The RSU acquisition price was $0, with each RSU representing one share.
Following the transaction, the director beneficially owned 1,512,798 shares directly. The filing also lists indirect beneficial ownership of 516,084 shares through Greybrook Health Inc. and 2,042 shares through Greybrook Realty Partners Inc.
Madryn and affiliated funds report beneficial ownership of 20,737,061 shares of Neuronetics, Inc. common stock, representing approximately 31.4% of the outstanding shares based on 66,124,820 shares outstanding as of July 31, 2025. The Schedule 13D/A amends a prior filing and consolidates holdings across multiple Madryn entities and advisers while clarifying that Madryn and the advisors may be deemed to have indirect beneficial ownership through their advisory and partnership roles.
The amendment also discloses executed sales: MHP II, MHP II Cayman and MSO sold specified tranches of shares under Rule 144 at about $3.72 per share, and it notes that Covered Persons generally disclaim beneficial ownership except that Avinash Amin holds 12,500 shares (<1%) directly.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 2,925,554 common shares, with an aggregate market value of $10,883,060.88. The filing lists Morgan Stanley Smith Barney LLC as the broker and indicates the shares are to be sold on NASDAQ with an approximate sale date of 08/08/2025.
The notice shows the shares were acquired on 12/10/2024 in connection with a Merger/Acquisition from the issuer and were paid for in cash. The filer reports nothing to report for securities sold in the past three months and includes the standard representation that they are not aware of any undisclosed material adverse information about the issuer.
Neuronetics, Inc. (STIM) filed a Form 144 reporting a proposed sale of 192,806 common shares with an aggregate market value of $717,238.32. The filing states the sale is expected on or about 08/08/2025 on NASDAQ and lists Morgan Stanley Smith Barney LLC as the broker. The shares were acquired on 12/10/2024 in a merger/acquisition transaction from the issuer and were paid for in cash. The filing reports 66,124,820 shares outstanding and notes Nothing to Report for sales in the past three months.
Neuronetics, Inc. (Form 144) filed a notice proposing the sale of 381,640 shares of Common stock through Morgan Stanley Smith Barney LLC on the NASDAQ, with an approximate sale date of 08/08/2025 and an aggregate market value of $1,419,700.80 against 66,124,820 shares outstanding. The shares to be sold were acquired from the issuer in a merger/acquisition on 12/10/2024.
The filing shows the purchase was paid in cash on 12/10/2024, reports no securities sold in the past three months, and includes the required signer representation that the seller is not aware of undisclosed material adverse information about the issuer. The notice identifies the executing broker and the exchange but provides no further financial results or forward guidance.
FAQ
What is the current stock price of Neuronetics (STIM)?
What is the market cap of Neuronetics (STIM)?
